Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986488 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986488 Monotherapy | EXPERIMENTAL | - |
| Part 1B: BMS-986488 + Adagrasib | EXPERIMENTAL | - |
| Part 1C: BMS-986488 + Adagrasib + Cetuximab | EXPERIMENTAL | - |
| Part 1D: BMS-986488 + Nivolumab | EXPERIMENTAL | - |
| Part 2A: BMS-986488 Monotherapy | EXPERIMENTAL | - |
| Part 2B: BMS-986488 + Adagrasib | EXPERIMENTAL | - |
| Part 2C: BMS-986488 + Adagrasib + Cetuximab | EXPERIMENTAL | - |
| Part 2D: BMS-986488 + Nivolumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986488 | DRUG | Specified dose on specified days |
| Adagrasib | DRUG | Specified dose on specified days |
| Cetuximab | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participant must be ≥ 18 years of age. * Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:. * Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC),...
BMS-986488 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of advanced malignant tumors. It is currently in Phase 1 clinical development and is being studied both as a monotherapy and in combination therapy in adult patients with advanced solid tumors.
BMS-986488 is being evaluated for the treatment of advanced malignant tumors in adults. It is an investigational therapy in Phase 1 testing and is not yet approved for any indication. The trial enrolls patients with advanced malignant tumors and includes biomarker-selected participants.
BMS-986488 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb is the sponsor of the ongoing Phase 1 clinical trial evaluating the compound in patients with advanced malignant tumors.
BMS-986488 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA for any indication. The single ongoing Phase 1 trial is currently recruiting participants with advanced malignant tumors.
BMS-986488 is being studied in one Phase 1 clinical trial, NCT06764771, titled A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors. The trial is recruiting, has an estimated enrollment of 437 participants, and is conducted in the United States, Australia, and Canada.